A 10-year-old girl with aplastic anemia received an allogeneic bone marrow transplantation (BMT). Three years after an uneventful course apart from chronic graft-versus-host disease (GVHD) she presented with chronic hypoxemia, reduced diffusion capacity of the lungs, normal spirometric lung function and increased bilirubin and liver enzymes. Intrapulmonary vascular dilatations were demonstrated. Pulmonary complications after BMT may include a hepatopulmonary syndrome (liver disease, hypoxemia, intrapulmonary vascular dilatations).
Pulmonary complications after allogeneic bone marrow transplantation are a major cause of post-transplant morbidity and mortality and occur in about 50% of marrow recipients. They can be divided into infectious and noninfectious etiologies. 1 The latter include pulmonary edema, pulmonary hemorrhage, lymphocytic bronchitis, idiopathic pneumonia, bronchiolitis obliterans organizing pneumonia, and bronchiolitis obliterans.
We report a young female with aplastic anemia who had received an allogeneic BMT and developed chronic cyanosis and dyspnoea, pronounced on mild exercise. There was no evidence for chronic obstructive or restrictive pulmonary disease. Diffuse intrapulmonary vascular dilatations were found to be responsible for the hypoxemia. This disease entity has not previously been described as a pulmonary complication of BMT and must be considered in the differential diagnosis of progressive respiratory impairment.
Case report
In May 1988, a 6-year-old female developed chronic aplastic anemia that was diagnosed and managed until February 1991 at the Department of Pediatrics, Karl-Marx University, Leipzig, German Democratic Republic. Hyperimmunoglobulin and anti-D had no effect, and the disease was only partially responsive to prednisolone and the anabolic steroid metenolone. The latter was initiated in October 1990 at 2 mg/kg body weight/day for 4 weeks and then gradually tapered off until February 1991. During this time all liver function values were within the normal ranges and there was no evidence of hepatotoxicity. Because of increasing requirement for red blood cell and platelet transfusions and significant side-effects from the medication including virilization, weight gain and acne, she was referred to our clinic for BMT at the age of 9. years. Further conservative management was not successful; the platelet counts were between 1000 and 13 000/l, granulocytes between 800 and 2000/l and she required red blood cell transfusions one to two times a month. At the age of 10. years she received an allogeneic BMT (6.9 ϫ 10 8 nucleated cells isolated by gelatine sedimentation/kg body weight) from her HLA-identical sister after conditioning with endoxan and equine anti-thymocyte globulin. Her pretransplant liver function values, liver ultrasound, chest Xray, and lung function tests (transcutaneous oxygen saturation and spirometry since diffusion capacity was not routinely measured at that time in our children), were all normal. There was no family history of hematological, vascular or liver abnormalities. GVHD prophylaxis was started with methotrexate (15 mg/m 2 on 3 days) and cyclosporine (5-3-2-1 mg/kg body weight) for 1 year (Figure 1 ). She had no acute GVHD, but developed de novo mild chronic GVHD. This presented with abnormal liver function (bilirubin 1.1-1.5 mg/dl, AST 20-26 U/l), a very dry skin, chronic conjunctivitis and loose stools, which responded only partially to cyclosporine. Her course for 2. years after BMT was otherwise uneventful. She then insidiously developed dyspnoea on exercise and recurrent episodes of bronchitis. Three years after BMT she presented with cyanosis of her lips and the oxygen saturation was 80% at rest ( Figure 1 ).
Initially, normal spirometric and body plethysmographic lung function (FEV1 = 97% and FVC = 89% of predicted) were found. Chest X-ray, HR-CT scan, inhalation-perfusion scintigraphy, ECG and echocardiography were all normal. Hemoglobin, platelets, white blood cells, and serum chemistry were normal, except for slightly abnormal liver function (bilirubin 1.7 mg/dl, AST 30 U/l, ALT 20 U/l). The Immunosuppressive medication (cyclosporine, orally (black), by inhalation (grey), oxygen saturation (sitting), spirometric lung function (FEV1 = forced expiratory volume in 1 s) and diffusion capacity (corrected for hemoglobin) of the patient (weight 50 kg). Spirometric lung function testing was done on two occasions before BMT and the results were reported to be normal. However, the exact numbers of FEV1 are no longer available. diffusion capacity for CO was 47% of that predicted ( Figure 1 ). On exercise her arterial PO 2 dropped to 43 mmHg (from 64 mmHg resting) with no changes in the pCO 2 (28 mmHg) or pH 7.48. She was diagnosed as having severe hypoxemia with pulmonary diffusion impairment due to pulmonary manifestations of chronic GVHD.
Immunosuppression was started again with cyclosporine at doses to maintain blood levels between 400 and 550 ng/ml, and with high doses of methylprednisolone (Figure 1 ). During this time period her body weight Figure 2 Tc-99m labeled macro-aggregated albumin was injected into a peripheral vein. Fifty one percent of the total radioactivity was localized to the brain, thyroid gland, liver and the kidneys. Only 49% was located to the lungs. Normally more than 95% of the label is trapped in the lungs. In the absence of cardiac shunts this demonstrates substantial dilatations of the pulmonary capillaries.
increased from 50 to a maximum of 67 kg. Liver function did not improve significantly. She developed massive striae, increased blood pressure and was very aggressive. The family and patient did not want further oral steroids and these were tapered (Figure 1 ). Continuous treatment with inhaled budesonide (2 ϫ 400 g via turbohaler) was started, along with azathioprine.
To make a more precise diagnosis an open lung biopsy and bronchoalveolar lavage were performed. The lavage was normal (total cell count 5.6 ϫ 10 6 , with 94% macrophages, 5% lymphocytes, 1% neutrophils), all cultures for microorganisms being negative. Histopathology showed no evidence of obliterating bronchiolitis, interstitial fibrosis or viral pneumonia. In the alveolar region, a diffuse but very mild impairment of the normal structure was noted with a focal proliferation of type II pneumocytes, accumulation of mast cells and deposition of fibrous material. This was in agreement with a further normal spiral CT scan of the lungs, but did not explain the hypoxemia which was more pronounced when changing from the supine (O 2 -Sat. 89%) to the standing position (O 2 -Sat. 77%) and which normalized with breathing oxygen (FiO 2 = 1.0; O 2 -Sat. 99-100%). On contrast echocardiography, microbubbles from agitated normal saline injected into the brachial vein, which are normally trapped and absorbed by the pulmonary capillaries were clearly demonstrated as appearing in the left heart chambers, with a delay of 3-5 cardiac contractions, after visualization on the right hand side. This suggested intrapulmonary dilatations. These were confirmed by a technetium-99 macroaggregated albumin body scan. Fiftyone percent of the injected albumin was found outside the lungs, mainly in the brain, kidneys and liver (Figure 2) . Catheterization of the heart and pulmonary angiography excluded the presence of intracardiac shunts or discrete vascular malformations of the lungs. Taken together, the results clearly demonstrated the presence of diffuse intrapulmonary vascular dilatations.
We hypothesized that the chronic pulmonary GVHD might be responsible and administered cyclosporine by inhalation (Figure 1) . However, no significant improvement occurred over a period of 6 months and we switched back to oral cyclosporine. The patient received continuous oxygen via nasal cannulae. From the time of presentation with cyanosis of the lips 36 months after bone marrow transplantation, the bilirubin was permanently elevated to levels between 1.2 and 2.0 mg/dl for the ensuing 4 years and AST and ␥-GT were constantly increased to no more than about twice the upper normal limit. Repeat blood tests ruled out known infectious and autoimmune conditions as causes of the liver disease. Ultrasound revealed mild fatty infiltration of the liver and a normal spleen with no evidence of portal hypertension. A blind liver biopsy showed a mild chronic portal inflammatory reaction, compatible with mild chronic GVHD, but with no characteristic signs of cirrhosis or fibrosis. Fibrinogen, albumin, cholinesterase and prothrombin times were always normal. Recently the patient was noted to have developed a small cutaneous vascular malformation resembling an arterio-venous naevus below the right eye as well as several spider naevi on the trunk.
Discussion
Chronic hypoxemia and intrapulmonary vascular dilatations have not been reported after bone marrow transplantation. Pulmonary vascular dilatations are a common complication of liver disease, known as hepatopulmonary syndrome (HPS). 2, 3 This syndrome consists of the triad of liver disease, hypoxemia and intrapulmonary vascular dilatations. In our patient the latter were demonstrated by two independent methods: contrast-enhanced echocardiography and technetium-99 macroaggregated albumin lung perfusion scan. Histo-pathological post-mortem perfusion studies of the lungs from patients with liver cirrhosis have identified dilatations of pulmonary precapillary and capillary vessels of about 15-500 m in diameter. 2, 4 However, such changes cannot been seen in routine biopsy specimens. Other vascular abnormalities are larger arterio-venous communications or pleural spider nevi. The mechanism(s) which lead to the hypoxemia are not completely understood. The intrapulmonary dilatations result in a diffusion-perfusion defect; with increased width of the capillary vessels the oxygen molecules have difficulty in reaching the center of the mixed venous bloodstream and the midstream erythrocytes fail to oxygenate, resulting in various degrees of hypoxemia. 2, 3 This can be partially overcome by increasing the inspired oxygen concentration, in contrast to true anatomic intrapulmonary shunts which do not respond so well to oxygen. Because these vascular abnormalities predominate in the middle to lower lung fields where gravitational effects result in increased blood flow, worsening of hypoxemia can occur in the upright position 4 as in our patient. They also explain the reduced diffusion capacity for CO in the absence of pronounced changes in the alveolar unit within the biopsy specimen.
The other features required for a diagnosis of HPS, such as liver disease, are clearly present but less pronounced in our patient. A consistent finding was elevated levels of bilirubin, AST, ␥GT and a mild inflammatory reaction in the liver biopsy. As seen in many other patients after allogeneic bone marrow transplantation these changes are assumed to be the result of chronic GVHD. 5 Alternative causes, such as the drugs used for treatment appear to be less likely in this case. The short course of metenolone was completed more than 1 year before BMT and was not associated with any changes in liver values or oxygen saturation, which were normal all that time. After BMT cyclosporine was used primarily and no associations with liver or lung symptoms were noted. Therefore BMT and the associated chronic GVHD which was clearly present all the time, are the most likely causes of the liver involvement. Although a large number of liver diseases have been associated with HPS, 2 chronic GVHD or related immunological reactions after bone marrow transplantation with manifestations in various organs including the liver, has not yet been included. HPS has also been described in an 18-month-old patient with chronic graft rejection following liver transplantation, who acquired the syndrome 4.5 years later. 6 Despite many approaches, no consistent relations between the severity of liver disease and hypoxemia have been established in patients with HPS. 2, 3, 7 In fact, gas exchange abnormalities may occasionally predate hepatic disease 8 and a progressive decline in oxygenation can occur despite stable liver function. 2 Although in this patient the triad of significant hypoxemia, intrapulmonary vascular dilatations and chronic liver disease was present and justifies the diagnosis of HPS, liver disease appears to be rather mild. In other patients with HPS and more severe liver disease, liver transplantation also resulting in the resolution of the intrapulmonary vascular dilations, remains the only therapeutic option. 3, 7 To recommend this to our patient is very difficult, as long as the liver disease does not progress further and a precise cause-effect relation cannot be shown in a particular patient with HPS before liver transplantation is actually carried out. 3 The causes of the HPS are still unknown. They are generally believed to involve an imbalance between hepatic factors inhibiting and stimulating vascular cell growth or an imbalance between pulmonary vasoconstrictors and vasodilators, such as nitric oxide. 4 In our patient, who was receiving inhaled steroids, the latter was repeatedly normal in exhaled air (9 ppb nitric oxide at an expiratory flow of 184 ml/s). Except for some anecdotal reports, 2 other therapeutic approaches do not appear to be available.
In conclusion, the evaluation of pulmonary complications in patients after allogeneic bone marrow trans-plantation should include assessment for liver disease, hypoxemia and intrapulmonary vascular dilatations.
